Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019621 (
Langerhans cell histiocytosis
)
3,250
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Langerhans' cell histiocytosis
(
LCH
) is characterized by the presence of large mononucleated cells, associated with inflammatory cells. The Langerhans' cell (LC) lineage of the mononucleated cells is suggested by the presence of Birbeck granules and the expression of CD1a. We investigated the presence of 14 markers expressed by normal LCs in vitro. Nine skin and one lymph node frozen biopsies of
LCH
children were analysed by in situ immunohistochemistry. The data were compared with six skin and five lymph node frozen biopsies.
LCH
cells of the ten samples were positive for all 14 LC markers. We observed three different groups of markers, according to the respective staining of normal LCs and
LCH
cells. Group 1 included DR, DQ, CD1a, CD1c, and
ICAM-3
. Markers of group 1 were present on the majority of both normal LCs and
LCH
cells. Group 2 included CD1b, CD4, LFA-1, LFA-3, CD32, and CD68. Markers of group 2 were detected on the majority of
LCH
cells, but only on a fraction of normal LCs. Group 3 included CD11b, CD24, and B7/BB1. Markers of this group were detected on
LCH
cells, but not on normal LCs. This in situ immunohistochemical study confirms that
LCH
cells belong to the LC lineage. The different clinical
LCH
syndromes had the same immunohistochemical staining. The expression of some markers of groups 2 and 3 is known to be related to the activation of LCs in vitro. Our study suggests that
LCH
cells are activated LCs.
...
PMID:Langerhans' cell histiocytosis cells are activated Langerhans' cells. 796 9
ICAM-3
is a newly recognized adhesion molecule, which is a member of the immunoglobulin supergene family of ICAMs, and has been shown to be identical with the
CD50
antigen. Recent functional studies have shown that
ICAM-3
is a ligand for LFA-1, and plays an important part in immune reactions. To date, very few data exist in the literature concerning its expression in the skin. In the present study, we investigated the expression of
ICAM-3
in normal skin and in 98 biopsy specimens of various inflammatory and neoplastic dermatoses.
ICAM-3
was found to be expressed by epidermal CD1a+ Langerhans cells, by cells of
Langerhans cell histiocytosis
, by T and B lymphocytes infiltrating the dermis in cutaneous lymphomas and in a wide spectrum of inflammatory dermatoses. Epidermal keratinocytes were consistently negative; endothelial expression of
ICAM-3
was observed in six of the 98 cases. These results show that
ICAM-3
is constitutively and widely expressed by cells participating in inflammatory dermatoses (including Langerhans cells and T and B lymphocytes), and that it can be, albeit rarely, induced on endothelial cells and dermal dendrocytes. These results highlight the important part that
ICAM-3
may play in cutaneous inflammatory and immune reactions.
...
PMID:Expression of ICAM-3/CD50 in normal and diseased skin. 854 91